Researchers identified a molecular pathway that can limit muscle repair, a finding that may guide future muscular dystrophy treatments.

CAMBRIDGE, England--(BUSINESS WIRE)--bit.bio, the company coding human cells for novel cures, today launches its first set of muscle cell disease model products designed to advance the discovery and ...

Researchers in the Division of Nutritional Sciences have identified a molecular mechanism that constrains skeletal muscle regeneration and myofiber ...

Satellos Bioscience Inc. has reported results from preclinical studies in a disease model of Duchenne muscular dystrophy (DMD). The company's proprietary Myoregenx assay platform identified a protein ...

TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the ...

Blocking a certain type of ion channel has been shown to prolong survival in mouse models of severe Duchenne muscular dystrophy (DMD), which could lead to the development of novel treatments in humans ...

Scientists have so far identified around 800 different neuromuscular diseases. These conditions are caused by problems in the way muscle cells, motor neurons and peripheral cells interact. These ...

The drug target for the Duchenne program is AAK1, a protein kinase in the Notch pathway, which the Company discovered can be modulated to enable muscle regeneration Satellos is conducting IND-enabling ...

University of Delaware’s Mona Batish is a molecular biologist. She studies circular RNAs formed as a result of so-called molecular mistakes that occur when a strand of RNA — the ribonucleic acid that ...

TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB: MSCLF), a publicly traded biotech company developing new small molecule therapeutic approaches to ...